Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases

Sponsor
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Study ID
NCT06970951
Phase
EARLY_PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • UTAA91 injection — BIOLOGICAL
    Infusion of UTAA91 injection in subjects screened after signing informed consent.

Study Details

This clinical trial is designed as a single - arm, open - label, single - center, investigator - initiated early - phase clinical study. The primary objective is to evaluate the safety of UTAA91 injection in treating subjects with relapsed/refractory autoimmune inflammatory diseases (AID).

Key Dates

First listed
May 14, 2025
Start date
May 18, 2025
Status verified
May 2025
Primary completion
Jun 30, 2026
Completion
Apr 30, 2027

Study Design

Enrollment
15 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: UTAA91 injection
    Infusion of UTAA91 injection in subjects screened after signing informed consent.

Primary Outcome Measure

Adverse events [ Time Frame: About 1 year ]

Central Contacts

Find similar trials

Nationwide
Rheumatoid arthritis trialsLupus (SLE) trialsRheumatology trialsAutoimmune disease trialsMusculoskeletal disorders trials

Related Studies